Vabrinty Injection, Suspension, Extended Release
Product Images NDC 85043-075

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Vabrinty (NDC 85043-075). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Uronova Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mixing (Vabrinty 1)

Illustration showing the contents of the Vabrinty injection tray, including two syringes labeled A and B connected by a coupling device with a latching button, and a separate safety needle and cap assembly with a needle hub and safety shield.*

FDA Label Image

Admin (Vabrinty 10)

An instructional illustration showing two methods to activate or unlock a syringe device for injection. Both methods involve a 'click' action, either by pushing a part of the syringe with a thumb or by pressing a lever with a finger. The syringe is held in a hand in each method.*

FDA Label Image

Structure (Vabrinty 11)

Chemical structure of leuprolide acetate, the active ingredient in Vabrinty injection, suspension, extended release.*

FDA Label Image

Figure 4 (Vabrinty 12)

A line graph showing serum testosterone concentration (ng/dL) on the vertical axis over a period of 6 months post baseline on the horizontal axis. The graph includes six marked injection points indicating times of injections, with a notable sharp decline in testosterone levels shortly after the first injection, stabilizing at lower levels thereafter.*

FDA Label Image

Figure 5 (Vabrinty 13)

A line graph showing serum testosterone concentration (ng/dL) over months post baseline. The x-axis represents months up to 6 months, and the y-axis represents serum testosterone concentration ranging from 0 to 700 ng/dL. Two injections are marked: Injection #1 near baseline and Injection #2 around 3 months. Testosterone levels drop sharply after the first injection and remain low through 6 months.*

FDA Label Image

Figure 6 (Vabrinty 14)

A line graph showing serum testosterone concentration (ng/dL) over a period of 8 months post baseline. The graph marks two injection points at month 0 and month 4, depicting a rapid decrease in testosterone concentration following the first injection and sustained low levels thereafter.*

FDA Label Image

Figure 6 (Vabrinty 15)

A line graph depicting serum testosterone concentration (ng/dL) over 12 months post baseline. It shows a sharp decline in testosterone levels shortly after Injection #1, followed by sustained low levels with a minor event marked at Injection #2 around month 6.*

FDA Label Image

Mixing (Vabrinty 16)

An instructional diagram showing components of an injection assembly and safety needle for Vabrinty. The syringe assembly includes Syringe A, Syringe B, and a coupling device with a latching button. The safety needle includes a needle hub, safety shield, and cap, with labels indicating their positions under the tray.*

FDA Label Image

Step 2 (Vabrinty 17)

An instructional diagram illustrating the connection of two syringes labeled Syringe A and Syringe B via a coupling device that has a latching button. The image shows hands holding Syringe A and pressing the coupling device to attach Syringe B.*

FDA Label Image

Step 3 (Vabrinty 18)

Instructional diagram showing a syringe with labeled pushes: Push A moves the plunger forward, and Push B pulls it back. The cycle consists of alternating Push A and Push B actions, repeated 60 times. The image illustrates the operation of a hand-driven mechanism, likely for mixing or preparing an extended-release suspension injection.*

FDA Label Image

Step 4 (Vabrinty 19)

An instructional diagram showing a hand pressing down on Syringe A to push its contents into Syringe B below. The image visually demonstrates the process of combining or transferring medication between two syringes, labeled as Syringe A and Syringe B.*

FDA Label Image

Step2 (Vabrinty 2)

Illustration shows hands assembling a dual-syringe injection system labeled Syringe A and Syringe B connected by a coupling device with a latching button, demonstrating the preparation of a medication injection suspension for administration.*

FDA Label Image

Step 5 (Vabrinty 20)

An instructional diagram showing a hand holding Syringe A being pulled upwards while another hand holds Syringe B, which is being rotated clockwise. The illustration appears to guide on how to manipulate or prepare the two syringes, likely for use with Vabrinty (leuprolide acetate) injection.*

FDA Label Image

Step 6 (Vabrinty 21)

An instructional illustration showing gloved hands demonstrating the attachment of Syringe B by pressing it downward onto another syringe or device. The diagram is intended to guide proper assembly technique for a medical injection system.*

FDA Label Image

Step 7 (Vabrinty 22)

An instructional illustration demonstrating a hand wearing a glove pulling back on the plunger of Syringe B to draw solution, with a needle attached at the tip. The image shows the assembly and preparation of a syringe for injection.*

FDA Label Image

Admin 1 (Vabrinty 23)

An instructional illustration depicting a hand pinching the skin of an arm, indicating preparation for a subcutaneous injection.*

FDA Label Image

Admin (Vabrinty 24)

An instructional diagram showing a hand administering a subcutaneous injection at a 90-degree angle into the skin. A syringe is inserted into the skin, demonstrating proper injection technique for a subcutaneous route.*

FDA Label Image

Admin (Vabrinty 25)

An instructional illustration showing two methods to activate or prepare a pre-filled injection device, both indicating a "Click" sound. The left side depicts pressing or twisting the syringe, while the right side shows a similar "Click" activation by pressing a button or cap with a thumb. The image is likely related to the use of a subcutaneous injection product.*

FDA Label Image

22.5 mg (Vabrinty 26)

Packaging label for Vabrinty 22.5 mg injection suspension, extended release, for subcutaneous use. The label indicates each dose is every 3 months, contains the generic name Leuprolide acetate, and is produced by URONOVA Pharmaceuticals, Inc. It specifies that the product is Rx only with detailed storage and usage instructions.*

FDA Label Image

22.5 mg (Vabrinty 27)

Packaging label for Vabrinty injection, suspension, extended release by Uronova Pharmaceuticals, Inc. It includes a QR code and directions to scan the code to review the vial's instructions for use. The label advises completing the enclosed guide before preparing and administering Vabrinty.*

FDA Label Image

45 mg (Vabrinty 28)

Vabrinty 45 mg injection, suspension, extended release in a single-dose package for subcutaneous use by URONOVA PHARMACEUTICALS, INC. The label indicates it is for a 6-month dose and includes preparation instructions, storage details, and the NDC code 05043-045-04. The packaging is blue and white with detailed drug and usage information.*

FDA Label Image

45 mg (Vabrinty 29)

Flat cardboard carton packaging for Vabrinty injection, suspension, extended release. It features a blue panel with instructions including scanning a QR code to view administration instructions and to consult the package guide for correct preparation and mixing. The label mentions use under a provider's care but shows no dosage or ingredient details. The labeler is not explicitly shown on this panel.*

FDA Label Image

Step3 (Vabrinty 3)

An instructional diagram showing the operating cycle of a dual-chamber syringe for injection. It illustrates two push actions labeled 'Push A' and 'Push B' in opposite directions, indicating one complete cycle. The instructions note to repeat this cycle 60 times, likely to mix or prepare the suspension before administration.*

FDA Label Image

Step4 (Vabrinty 4)

An instructional illustration showing hands mixing two syringes labeled Syringe A and Syringe B by pushing Syringe A down into Syringe B. The diagram likely demonstrates preparation steps for the Vabrinty injection suspension.*

FDA Label Image

Step5 (Vabrinty 5)

An instructional illustration showing how to connect Syringe A and Syringe B for mixing or preparation. One hand holds Syringe B steady while the other hand attaches and twists Syringe A onto Syringe B, with an upward arrow indicating the direction for Syringe A.*

FDA Label Image

Step6 (Vabrinty 6)

An instructional illustration showing a gloved hand holding and pressing down a syringe labeled 'Syringe B' onto another syringe, demonstrating a step in medication preparation or administration technique.*

FDA Label Image

Step7 (Vabrinty 7)

An instructional diagram showing the correct technique to remove a syringe cap labeled 'Syringe B' by pulling it straight up, with a hand holding the syringe and an arrow indicating upward movement.*

FDA Label Image

Admin1 (Vabrinty 8)

An instructional illustration showing a hand pinching the skin on an arm, likely demonstrating preparation for subcutaneous injection placement. No text or branding is visible in the image.*

FDA Label Image

Admin (Vabrinty 9)

An instructional illustration showing a hand administering a subcutaneous injection using a syringe at a 90-degree angle into the skin fold of an arm or thigh. The image demonstrates correct technique for subcutaneous injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.